Sharat Koul, DO
Interventional Cardiology · Nicholasville, KYNPI 1093986614
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,623 of the $18,261 with a category attached, or 74.6%. It is spread thinly across 58 manufacturers, the largest accounting for just 14.1%. Reporting peaked in 2019 at $5,731 and has fallen 56.1% since, to $2,517 in 2025.
Across 459 payments — averaging $39.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Boston Scientific$2K
- Bolton Medical Inc$1K
- Endologix LLC$1K
- Avinger Inc.$1K
- Abbott$1K
- plus $9K from 52 others
What the payments were for
- Travel & lodging$4,63825%
- Food & beverage$13,62375%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$1,850
- ANGIOJET$1,277
- TREO ABDOMINAL STENT-GRAFT SYSTEM$1,170
- PANTHERIS$875
- Navicross$843
- AZUR$843
- GlideWire$843
- Indigo System$731
- Serrantor$701
- AFX$483
- ENROUTE Transcarotid Neuroprotection System$315
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$303
- MitraClip$200
- Ovation iX Iliac Stent Graft$172
- ARTIX MT$168
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$158
- ENROUTE Transcarotid Stent$158
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$154
- Ovation$150
- Alto Abdominal Stent Graft System$146
How this compares
$18,261 in reported general payments places this provider in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 91 | $93,605 |
| EliquisApixaban | 42 | $43,401 |
| EntrestoSacubitril/Valsartan | 38 | $39,110 |
| Repatha SureclickEvolocumab | 30 | $35,076 |
| BrilintaTicagrelor | 35 | $19,609 |
| JardianceEmpagliflozin | 15 | $15,256 |
| Ranolazine ErRanolazine | 46 | $6,352 |
| ClopidogrelClopidogrel Bisulfate | 138 | $1,180 |
| Metoprolol Succinate | 84 | $732 |
| Rosuvastatin Calcium | 45 | $600 |
| Atorvastatin Calcium | 88 | $520 |
| Bisoprolol Fumarate | 13 | $468 |
| Potassium Chloride | 55 | $465 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $387 |
| Isosorbide Dinitrate | 12 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $338 | $93,60591 claims |
| PfizerEliquis | $703 | $43,40142 claims |
| NovartisEntresto | $886 | $39,11038 claims |
| AstraZenecaBrilinta | $82 | $19,60935 claims |
| Boehringer IngelheimJardiance | $29 | $15,25615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Nicholasville
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ashish RastogiOwensboro$123K
- Armaghan SoomroLexington$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.